on Newron Pharmaceuticals S.p.A. (isin : IT0004147952)
Newron Pharmaceuticals Reports 2024 Financial Results, Previews 2025
Milan-based Newron Pharmaceuticals S.p.A. released its 2024 financial results and shared its 2025 outlook. The biopharma company focuses on innovative therapies for central nervous system disorders. Key achievements in 2024 include promising data from studies on evenamide, a potential therapy for treatment-resistant schizophrenia (TRS). The drug demonstrated significant efficacy and safety, positioning it as an innovative option for patients who don’t respond to current treatments.
Strategic partnerships further strengthened Newron’s position. An agreement with Japan’s EA Pharma in December 2024 and South Korea's Myung In Pharm in January 2025 focus on evenamide's development and commercialization. Financially, Newron reported a net profit of EUR 15.8 million, contrasting 2023’s losses, driven largely by license income of EUR 44.5 million. Cash resources are bolstered, supporting planned programs through 2026.
The 2025 outlook includes a pivotal Phase III trial for evenamide and potential market share registration in the USA. Further development and partnership opportunities remain priorities as Newron aims to expand its impact in the biopharmaceutical market.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Newron Pharmaceuticals S.p.A. news